Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis

Schizophrenia Research

Volumn 134, Issue 2-3, 2012, Pages 202-206

  Hecht, Eric Michael ^a   Landy, David C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha 2 antagonists; Meta analysis; Mianserin; Mirtazapine; Schizophrenia

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; MIANSERIN; MIRTAZAPINE; NEUROLEPTIC AGENT; PERPHENAZINE; PLACEBO; RISPERIDONE;

ADD ON THERAPY; ARTICLE; DEPRESSION; DRUG EFFICACY; HAMILTON SCALE; HUMAN; META ANALYSIS; NEGATIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; CONFIDENCE INTERVALS; DEPRESSION; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PUBMED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84856270110     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.11.030     Document Type: Article

References (29)

1. Abbasi S.H., Behpournia H., Ghoreshi A., et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr. Res. 2010, 116(2):101-106.
2. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 2004, 7(Suppl 1):S1-S5.
3. Beitinger R., Lin J., Kissling W., Leucht S. Comparative remission rates of schizophrenic patients using various remission criteria. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(7):1643-1651.
4. Berk M., Ichim C., Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int. Clin. Psychopharmacol. 2001, 16(2):87-92.
5. Berk M., Gama C.S., Sundram S., et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomized, placebo-controlled clinical trial. Hum. Psychopharmacol. 2009, 24(3):233-238.
6. Cho S.J., Yook K., Kim B., et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(1):208-211.
7. Devoto P., Flore G. On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons?. Curr. Neuropharmacol. 2006, 4(2):115-125.
8. Hayashi T., Yokita N., Takahashi T., Tawara Y., Nishikawa T., Yano T., Furutani M., Fujikawa T., Horiguchi J., Yamawaki S. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 1997, 12(4):199-205.
9. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α-2 adrenoceptor blockade. Science 1999, 286(5437):105-107.
10. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
11. Joffe G., Terevnikov V., Joffe M., et al. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr. Res. 2009, 108(1-3):245-251.
12. Kooyman I., Dean K., Harvey S., Walsh E. Outcomes of public concern in schizophrenia. Br. J. Psychiatry 2007, 50(Suppl):s29-s36.
13. Leucht S., Corves C., Arbter D., et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
14. Litman R.E., Su T.P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br. J. Psychiatry 1996, 168(5):571-579.
15. Marcus M.M., Jardemark K.E., Wadenberg M.L., et al. Combined α2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int. J. Neuropsychopharmacol. 2005, 8(3):315-327.
16. Millan M.J., Gobert A., Rivet J.M., et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur. J. Neurosci. 2000, 12(3):1079-1095.
17. Miyamoto S., Duncan G.E., Marx C.E., et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10(1):79-104.
18. Poyurovsky M., Koren D., Gonopolsky I., et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur. Neuropsychopharmacol. 2003, 13(2):123-128.
19. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987, 1(2):133-152.
20. Seeman M.V. An outcome measure in schizophrenia: mortality. Can. J. Psychiatry 2007, 52(1):55-60.
21. Shiloh R., Zemishlany Z., Aizenberg D., et al. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. Int. Clin. Psychopharmacol. 2002, 17(2):59-64.
22. Singh S.P., Singh V., Kar N., et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry 2010, 197(3):174-179.
23. Stenberg J.H., Terevnikov V., Joffe M., et al. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int. J. Neuropsychopharmacol. 2010, 13(4):433-441.
24. Svensson T. Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanisms of action. Clin. Neurosci. Res. 2003, 3(1-2):34-46.
25. Thornley B., Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998, 317(7167):1181-1184.
26. Wadenberg M.L., Wiker C., Svensson T.H. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive α2 adrenoceptor blockade: experimental evidence. Int. J. Neuropsychopharmacol. 2006, 10(2):191-202.
27. Wiker C., Linnér L., Wadenberg M.L., Svensson T.H. Adjunctive treatment with mianserin enhances effects of raclopride on cortical dopamine output and, in parallel, its antipsychotic-like effect. Neuropsychiatr. Dis. Treat. 2005, 1(4):356-372.
28. Zink M., Englisch S., Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr. Opin. Psychiatry 2010, 23(2):103-111.
29. Zoccali R., Muscatello M.R., Cedro C., et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 2004, 19(2):71-76.